Nyrada Inc (NYR) - Total Liabilities

Latest as of December 2025: AU$548.97K AUD ≈ $388.43K USD

Based on the latest financial reports, Nyrada Inc (NYR) has total liabilities worth AU$548.97K AUD (≈ $388.43K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Nyrada Inc (NYR) defensive interval to measure how many days the company can operate on defensive assets alone.

Nyrada Inc - Total Liabilities Trend (2018–2025)

This chart illustrates how Nyrada Inc's total liabilities have evolved over time, based on quarterly financial data. Check Nyrada Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.

Nyrada Inc Competitors by Total Liabilities

The table below lists competitors of Nyrada Inc ranked by their total liabilities.

Company Country Total Liabilities
Sinkang Industries Co Ltd
TW:2032
Taiwan NT$556.50 Million
Richmond International Travel & Tours Co Ltd
TWO:2743
Taiwan NT$1.96 Billion
Brii Biosciences Limited
F:7SS
Germany €36.20 Million
Pierce Group AB
ST:PIERCE
Sweden Skr452.00 Million
Popular Vehicles and Services Limited
NSE:PVSL
India Rs-6.28 Billion
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
Korea ₩136.13 Billion
Speciality Restaurants Limited
NSE:SPECIALITY
India Rs1.99 Billion
Kelly Services B Inc
NASDAQ:KELYB
USA $1.30 Billion

Liability Composition Analysis (2018–2025)

This chart breaks down Nyrada Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NYR total assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 19.00 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.06 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.05 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nyrada Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nyrada Inc (2018–2025)

The table below shows the annual total liabilities of Nyrada Inc from 2018 to 2025.

Year Total Liabilities Change
2025-06-30 AU$1.72 Million
≈ $1.22 Million
+101.40%
2024-06-30 AU$855.63K
≈ $605.41K
-5.59%
2023-06-30 AU$906.28K
≈ $641.25K
+75.81%
2022-06-30 AU$515.48K
≈ $364.73K
-22.53%
2021-06-30 AU$665.38K
≈ $470.80K
-10.16%
2020-06-30 AU$740.67K
≈ $524.07K
-87.85%
2019-06-30 AU$6.10 Million
≈ $4.31 Million
+34.52%
2018-06-30 AU$4.53 Million
≈ $3.21 Million
--

About Nyrada Inc

AU:NYR Australia Biotechnology
Market Cap
$74.53 Million
AU$105.33 Million AUD
Market Cap Rank
#20306 Global
#667 in Australia
Share Price
AU$0.43
Change (1 day)
-10.42%
52-Week Range
AU$0.33 - AU$1.38
All Time High
AU$1.38
About

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more